About this trial
A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Patient Profile
| Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC) |
Where’s this trial being run?
St James’s Hospital, St Vincents University Hospital, and University Hospital Limerick
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | BMS CA209-8HW |
|---|---|
| Number: | 18-08 |
| Full Title: | A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer |
| Principal Investigator: | Prof Ray McDermott (SVUH)/ Dr David Gallagher (SJH)/ Dr Osman Nemer (UHL) |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Bristol-Myers Squibb |
| Recruitment Started: |
Global: Q2 2019 Ireland: Q1 2021 |
| Global Recruitment Target: | 900 |
|---|---|
| Ireland Recruitment Target: | 10 |